Invitation Homes Inc
Change company Symbol lookup
Select an option...
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
BAC Bank of America Corp
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Blend
Company profile

Invitation Homes Inc. is a real estate investment trust. The Company owns and operates single-family homes for lease in the United States. With approximately 80,000 homes for lease in 16 markets across the United States, the Company has built a vertically integrated operating platform that enables to acquire, renovate, lease, maintain, and manage its homes. The Company's segment relates to acquiring, renovating, leasing and operating single-family homes as rental properties, including single-family homes in planned unit developments. The Company's home averages approximately 1,850 square feet with three bedrooms and two bathrooms. The Company's business activities encompasses property operations, marketing, leasing, digital marketing, resident relations, property maintenance, investment and asset management functions.

Postmarket

Last Trade
Delayed
$27.57
0.31 (1.14%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$27.26
Day's Change
-0.14 (-0.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.41
Day's Low
26.87
Volume
(Average)
Volume:
2,874,474

10-day average volume:
2,810,147
2,874,474

Global Sarcopenia Market Insights, Epidemiology and Forecasts, 2017-2019 & 2020-2030 - BIO101 (Biophytis) and Bimagrumab (Novartis) are the Major Players - ResearchAndMarkets.com

1:46 am ET September 15, 2020 (BusinessWire) Print

The "Sarcopenia - Market Insights, Epidemiology and Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

The market size of Sarcopenia is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Sarcopenia market size. Among EU5 countries, Italy had the highest market size, with USD 115.87 million in 2017, while Spain had the lowest market size of Sarcopenia, with USD 54.33 million in 2017.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Sarcopenia market or expected to get launched in the market during the study period 2017-2030. The analysis covers Sarcopenia market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

BIO101 (Biophytis) and Bimagrumab (Novartis) are the major players that are going to alter the market dynamics in the coming years, during the forecasted period 2020-2030.

Sarcopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics. The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Sarcopenia.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Sarcopenia domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Sarcopenia Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

In the coming years, Sarcopenia market scenario is not expected to experience a positive shift across the 7MM due to approved treatment options and a robust pipeline. Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Key Questions

Market Insights:

What was the Sarcopenia market share (%) distribution in 2017 and how it would look like in 2030? What would be the Sarcopenia total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)? What are the key findings pertaining to the market across 7MM and which country will have the largest Sarcopenia market size during the forecast period (2017-2030)? At what CAGR, the Sarcopenia market is expected to grow in 7MM during the forecast period (2017-2030)? What would be the Sarcopenia market outlook across the 7MM during the forecast period (2017-2030)? What would be the Sarcopenia market growth till 2030, and what will be the resultant market Size in the year 2030? How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden and unmet needs of Sarcopenia? What is the historical Sarcopenia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? What would be the forecasted patient pool of Sarcopenia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? What will be the growth opportunities in the 7MM concerning the patient population pertaining to Sarcopenia? Out of all 7MM countries, which country would have the highest prevalent population of Sarcopenia during the forecast period (2017-2030)? At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Sarcopenia treatment, along with the approved therapy? What are the current treatment guidelines for the treatment of Sarcopenia in the USA, Europe, and Japan? What are the Sarcopenia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.? How many companies are developing therapies for the treatment of Sarcopenia? How many therapies are developed by each company for Sarcopenia? How many are emerging therapies in mid-stage, and late stage of development for Sarcopenia treatment? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sarcopenia therapies? What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Sarcopenia and their status? What are the key designations that have been granted for the emerging therapies for Sarcopenia? What is the global historical and forecasted market of Sarcopenia?

Key Topics Covered:

1 Key Insights

2 Executive Summary of Sarcopenia

3 SWOT Analysis for Sarcopenia

4 Sarcopenia Market Overview at a Glance

4.1 Market Share (%) Distribution of Sarcopenia in 2017

4.2 Market Share (%) Distribution of Sarcopenia in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Definition and classification

5.3 Causes

5.4 Risk factors

5.5 Pathophysiology

5.6 Biomarkers

5.7 Relevance to other disease states

5.8 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Prevalent Population of Sarcopenia in 7MM

6.3 Assumption and Rationale: 7MM

7 Country-wise Epidemiology of Sarcopenia

7.1 The United States

7.1.1 Prevalent cases of Sarcopenia in the United States

7.1.2 Prevalence of Sarcopenia by Gender in the United States

7.2 Germany

7.3 France

7.4 Italy

7.5 Spain

7.6 The United Kingdom

7.7 Japan

8 Treatment and Management

8.1 Medical treatment directions

8.2 Guidelines

8.2.1 EWGSOP Guidelines

8.2.2 Asian Working Group for Sarcopenia (AWGS)

8.2.3 International Conference on Sarcopenia and Frailty Research (ICSFR)

8.3 Selective androgen receptor modulators (SARM)

8.4 Patient Journey

9 Unmet Needs

10 Emerging Therapies

10.1 Sarconeos: Biophytis

10.1.1 Product Description

10.1.2 Clinical Development

10.1.3 Safety and Efficacy

10.2 Bimagrumab: Novartis

11 Other Promising Therapies

11.1 LY2495655: Eli Lily

11.1.1 Product Description

11.2 Trevogrumab: Regeneron Pharmaceuticals/Sanofi

11.3 PF 1801: Immunoforge

11.4 PB1023: Immunoforge

12 Discontinued Therapies

12.1 Enobosarm : GTx

12.1.1 Product Description

13 Sarcopenia: 7 Major Market Analysis

13.1 Key Findings

13.2 Market Size of Sarcopenia in 7MM

13.3 United States

13.3.1 Total Market size of Sarcopenia

13.3.2 Sarcopenia Market Size by Therapies

13.4 EU5 Countries

13.4.1 Germany

13.4.2 France

13.4.3 Italy

13.4.4 Spain

13.4.5 United Kingdom

13.5 Japan

14 Market Drivers

15 Market Barriers

16 Appendix

Companies Mentioned

Biophytis Novartis Eli Lily Immunoforge Regeneron Pharmaceuticals Sanofi

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xgskc5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005963/en/

SOURCE: Research and Markets

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com 
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.